Disruption of neutrophil migration in a conditional transgenic model: evidence for CXCR2 desensitization in vivo.
We developed transgenic mice conditionally expressing the neutrophil chemoattracting chemokine KC and the beta-galactosidase gene in multiple tissues. In these transgenic mice, doxycycline treatment induced a strong up-regulation in the expression of KC in several tissues, including heart, liver, kidney, skin, and skeletal muscle. Expression of KC within these tissues led to a rapid and substantial increase in the serum levels of KC (serum KC levels were higher than 200 ng/ml 24 h after treatment). Accordingly, beta-galactosidase expression was also detected after injection of doxycycline and was highest in skeletal muscle, pancreas, and liver. Surprisingly, despite expression of KC in multiple tissues, no neutrophil infiltration was observed in any of the tissues examined, including skin. Doxycycline treatment of nontransgenic mice grafted with transgenic skin caused dense neutrophilic infiltration of the grafts, but not the surrounding host skin, indicating that the KC produced in transgenic tissues was biologically active. In separate experiments, neutrophil migration toward a localized source of recombinant KC was impaired in animals overexpressing KC but was normal in response to other neutrophil chemoattractants. Analysis of transgenic neutrophils revealed that high concentrations of KC in transgenic blood had no influence on L-selectin cell surface expression but caused desensitization of the receptor for KC, CXCR2. These results confirm the neutrophil chemoattractant properties of KC and provide a mechanistic explanation for the paradoxical lack of leukocyte infiltration observed in the presence of elevated concentrations of this chemokine.
Wiekowski
M T
MT
Department of Immunology and Human Genome Research, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. maria.wiekowski@spcorp.com
Chen
S C
SC
Zalamea
P
P
Wilburn
B P
BP
Kinsley
D J
DJ
Sharif
W W
WW
Jensen
K K
KK
Hedrick
J A
JA
Manfra
D
D
Lira
S A
SA
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D054360:Chemokine CXCL1; D019743:Chemokines, CXC; D002630:Chemotactic Factors / Q000235:genetics / Q000502:physiology*; D002634:Chemotaxis, Leukocyte; D015536:Down-Regulation; D004318:Doxycycline / Q000494:pharmacology; D005434:Flow Cytometry; D017930:Genes, Reporter; D006133:Growth Substances / Q000235:genetics / Q000502:physiology*; D036341:Intercellular Signaling Peptides and Proteins; D019041:L-Selectin / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009504:Neutrophils / Q000276:immunology*; D012333:RNA, Messenger / Q000096:biosynthesis; D023063:Receptors, Interleukin-8B / Q000378:metabolism*; D016038:Skin Transplantation / Q000276:immunology / Q000473:pathology; D014018:Tissue Distribution; D001616:beta-Galactosidase / Q000235:genetics / Q000378:metabolism
D000900:Anti-Bacterial Agents; D054360:Chemokine CXCL1; D019743:Chemokines, CXC; D002630:Chemotactic Factors; C475895:Cxcl1 protein, mouse; D006133:Growth Substances; D036341:Intercellular Signaling Peptides and Proteins; D012333:RNA, Messenger; D023063:Receptors, Interleukin-8B; D019041:L-Selectin; D001616:beta-Galactosidase; D004318:Doxycycline; D002118:Calcium